Highlights
IIA supported (ever)
About
Treatment for Drug-resistant Bacterial Infections
Zolex Therapeutics is a recently established drug company focusing on the development of new classes of orally active, small-molecular-weight antibiotics that target Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus strains. Zolex Therapeutics is located within the RadBioMed Accelerator at Ramat Hachayal, Tel Aviv, and is led by Dr. Lewis Neville and Dr. Ziv Lifshitz.
Identity
| Name | Zolex Therapeutics |
|---|---|
| Slug | zolex-therapeutics |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwKXK1pYKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2018 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | HaBarzel Street 27, Tel Aviv-Yafo, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsantibioticspharma-companiesantibodiesdrug-discoverybiopharmaceutical
Funding
| Total raised | $500K |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}